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Abstract
Background: Several evidences suggested that ovarian cancer (OC) patients showing isolated
lymph node recurrence (ILNR) have an indolent evolution. The aim of the study was to
retrospectively review ILNR observed in our Institution over the past 11 years in order to
investigate: the pattern of disease progression after the first diagnosis of ILNR, and their clinical
outcome.
Methods: Between September 1995 and September 2006, 523 epithelial OC were diagnosed in
our centers, and 301 of these relapsed. Cases with a diagnosis of ILNR, and at least 12 months of
follow up after the diagnosis of ILNR were included. Post-relapse survival (PRS) was recorded from
the date of the diagnosis of ILNR to the date of death or date last seen. Survival probabilities were
estimated according to the method of Kaplan and Meier and compared by the log rank test. Cox's
regression model with stepwise variable selection was used to analyse the role of clinico-
pathological parameters as prognostic factors for PRS.
Results: Thirty-two cases were identified as ILNR (10.6% of the recurrences, and 6.1% of the OC
population). Most of the patients continued to exhibit the same pattern of progression during
follow up, with 75% of the patients free from peritoneal disease after 2 years from the diagnosis of
ILNR. Median Post-Relapse Survival (PRS) was 37 months, and median Overall Survival (OS) was
109 months, with all patients surviving more than 2 years after the initial diagnosis. In multivariate
analysis only Platinum-Free Interval (PFI) retained a prognostic role for PRS (p value = 0.033).
Conclusion: ILNR represents a less aggressive pattern of OC relapse which keeps progressing in
the lymph nodes in a relatively high percentage of cases. On the other hand, the occurrence of
peritoneal spreading after ILNR is associated with a rapidly fatal outcome.
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Background
Ovarian cancer (OC) is the most lethal gynaecological
malignancy with the vast majority of patients succumbing
within 5 years from initial diagnosis [1]. A major clinical
challenge in OC is the management of the relapsing dis-
ease, which is almost always fatal within an estimated
median interval post-relapse-survival (PRS) of approxi-
mately 18 months [1,2]. A short duration of platinum-
free-interval (PFI) has been widely reported as a crucial
factor determining a short PRS [2-4]. Moreover, also the
pattern of recurrence has been shown to play a role in con-
ditioning the clinical outcomes: indeed, OC patients suf-
fering from recurrence with a prevalent pattern of diffuse
abdominal carcinomatosis exhibit an unfavourable prog-
nosis compared to cases presenting with discrete lesions,
regardless of PFI duration [2,5,6]. On the other hand, a
favourable prognosis has been recently documented for
patients with isolated lymph node relapses (ILNR), who
experience a median PRS ranging from 26 to 114 months,
according to the modality of treatment [7-10]. Several evi-
dences suggest that lymph node disease in OC may
progress in an indolent fashion; in particular i) the clinical
outcome of primary OC patients staged as FIGO stage IIIC
only on the basis of lymph node involvement is more
favourable compared to the prognosis of patients with
peritoneal FIGO stage III disease [11-14]; ii) retroperito-
neal residual tumor at second-look did not seem to influ-
ence survival [15]; iii) the clinical impact of systematic
lymphadenectomy at primary surgery is still a debated
issue in OC [16-18], thus suggesting a minor role of exten-
sive lymph node dissection compared to primary maxi-
mal surgical effort for intraperitonal disease. All this data
suggests that tumor cells metastasizing or recurring
through the lymphatic versus the transcoelomic route have
distinct, less aggressive biological features. While ILNR
could represent a peculiar setting in order to investigate
whether lymphophilic OC cells tend to have a distinct,
potentially indolent biologic behaviour, the natural his-
tory of disease after the diagnosis/treatment of ILNR has
been not yet addressed.
We retrospectively reviewed all cases of ILNR observed in
our Institution over the past 11 years in order to investi-
gate: i) the pattern of subsequent disease progression after
the first diagnosis of ILNR, and ii) the clinical outcome of
patients suffering from this peculiar pattern of relapse.
Methods
We conducted a retrospective analysis of all primary
untreated invasive OC patients consecutively admitted to
the Gynecologic Oncology Unit, Catholic University of
Rome and Campobasso between September 1995 and
September 2006. During this period 523 epithelial OC
were diagnosed and treated in our centers, and 301 of
these relapsed. The criteria for inclusion in the study were:
1) the initial diagnosis of epithelial invasive OC, 2) the
diagnosis of isolated lymph node relapse (ILNR) docu-
mented by CT scan and clinical examination, with or
without PET scan and/or histological confirmation, 3) at
least 12 months of follow up after the diagnosis of ILNR.
The study was approved by our institutional Ethical Com-
mittee, in compliance with the Helsinki Declaration http:/
/www.wma.net/e/policy/b3.htm. At time of analysis, 32
cases (10.6% of the recurrences, and 6.1% of the whole
OC population) developed ILNR, and fulfilled all the
inclusion criteria. Patients' characteristics at initial diag-
nosis are detailed in Table 1: median age was 60 years
(range 45–76), and most of the patients (90.6%) were
staged as FIGO stage IIIC-IV disease. At initial diagnosis
all patients underwent exploratory laparotomy with
cytoreductive intent: cytoreduction to residual disease <
0.5 cm was achieved in 14 (43.7%) patients, while a resid-
ual disease between 0.5 and 2 cm was obtained in 6
(18.7%) cases. Pelvic and/or aortic lymphadenectomy
was performed in cases with grossly involved lymph
nodes (n = 10, 31.2%), with 6 cases showing evidence of
metastatic lymph node involvement. Disease was consid-
ered primarily unresectable at time of primary laparotomy
in 12 cases (37.5%), and in 8 of them a second attempt of
cytoreduction (interval debulking surgery) was performed
given the achievement of a clinical response to chemo-
therapy, All patients underwent six cycles of cisplatin-
based chemotherapy with (n = 26), or without (n = 6)
paclitaxel. Follow up procedures were performed accord-
ing to institutional guidelines [19]. For each ILNR, infor-
mation on date of recurrence, pattern of disease
presentation (single versus multiple lesions, site, size),
Ca125 level and specific treatment were collected and
entered into a computerised database. The definition of
clinical relapse, i.e. physical evidence of cancer upon
examination and imaging (CT scan +/- PET scan +/- histol-
ogy) was used so as to be consistent with the literature
which uses this end point, as the basis for the time-ori-
ented definitions of 'sensitive/resistant/refractory' relapse
[20]. The date and site (i.e. lymph node versus perito-
neum versus parenchyma) of second, third and further
recurrences were also recorded. The interval between first
ILNR and the appearance of peritoneal disease was also
calculated. The choice of ILNR treatment depended on
recurrence characteristics (single or multiple sites, dura-
tion of PFI), previous treatments, patient's performance
status, and changes in treatment approaches over the
duration of the study. In particular, cytoreductive surgery
for ILNR was preferentially attempted in patients with sin-
gle/discrete number of sites of disease, PFI>6 months and,
good performance status. Post-relapse survival (PRS) was
recorded from the date of the diagnosis of ILNR to the
date of death for disease or date last seen. Overall survival
(OS) was recorded from the date of the initial diagnosis of
OC to the date of death for disease or date last seen. Sur-BMC Cancer 2008, 8:367 http://www.biomedcentral.com/1471-2407/8/367
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vival probabilities were estimated according to the
method of Kaplan and Meier and compared by the log
rank test [21,22]. Cox's regression model with stepwise
variable selection [23] was used to analyse the role of clin-
ico-pathological parameters as prognostic factors for PRS:
only variables with p value < 0.10 in the univariate analy-
sis were included in the multivariate analysis. Statistical
analysis was carried out using SOLO (BMDP Statistical
Software, Los Angeles, CA) and Statview survival tools
(Abacus Concepts- Inc- Berkeley CA).
Results
Clinico-pathological characteristics of the study 
population at the diagnosis of ILNR
Patients' characteristics at time of diagnosis of ILNR are
detailed in Table 2: median age was 62.5 years (range 46–
79), and median PFI was 17.5 months (range 1–134) with
Table 1: Clinical/pathological characteristics of OC patients at 
initial diagnosis
Characteristics No. (%)
All cases 32
Age, years
Median (range) 60 (45–76)
FIGO Stage
II 1 (3.1)
IIIB 2 (6.2)
IIIC 27 (84.4)
IV 2 (6.2)
Histotype
Serous 26 (81.2)
Endometrioid 2 (6.2)
Mucinous 1 (3.1)
Undifferentiated 3 (9.4)
Grade
G1-2 9 (28.1)
G3 19 (59.4)
n.a. 4 (12.5)
Ascites
No 16 (50.0)
Yes 12 (37.5)
n.a. 4 (12.5)
Ca125, IU/ml
Median (range) 1,121 (11-9,082)
Peritoneal carcinomatosis
No 11 (34.4)
Yes 21 (65.6)
Lymph node status (CT/Surgery)
Positive 19 (59.4)
Negative 13 (40.6)
Aortic +/- pelvic lymph node node sampling
Yes 10 (31.2)
No 22 (68.8)
Residual tumor at 1st surgery (cm)
< 0.5 14 (43.7)
0.5 – 2 6 (18.7)
> 2 12 (37.5)
First line Chemotherapy
Platinum-based 6 (18.7)
Platinum/taxane-based 26 (81.3)
Table 2: Clinical/pathological characteristics of OC patients at 
diagnosis of ILNR
Characteristics No (%)
Age, years
Median (range) 62.5 (46–79)
PFI, months
Median (range) 17.5 (1–134)
Diagnosis of 1st recurrence
CT scan 15 (46.9)
CT+PET scan 5 (15.6)
Surgery+CT scan 7 (21.9)
Surgery+CT+PET scan 5 (15.6)
Site of 1st ILNR
Para-aortic 14 (43.7)
Pelvic + Para-aortic 9 (28.1)
Pelvic 1 (3.1)
Groin 2 (6.2)
Axillary 1 (3.1)
Mediastinum 2 (6.2)
Other sites/combination 3 (9.4)
Number of lymph node recurrences
Single 13 (40.6)
Multiple 19 (59.4)
Size of the largest lesion, cm
Median (range) 2.2 (1.0–6.0)
Ca125 IU/ml
Median (range) 125 (8–1257)
Treatment of 1st ILNR
Chemotherapy 19 (59.4)
Surgery + chemotherapy 11 (34.4)
Surgery 1 (3.1)
Not treated 1 (3.1)BMC Cancer 2008, 8:367 http://www.biomedcentral.com/1471-2407/8/367
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9 patients (28.1%) recurring within 12 months from the
completion of first line chemotherapy. The diagnosis of
ILNR was based on CT scan findings in 15 (46.9%) cases,
combined PET/CT in 5 (15.6%) cases and surgical assess-
ment in 12 (37.5%) patients. Para-aortic lymph node sta-
tions without (n = 14, 43.7%) or with pelvic lymph node
stations (n = 9, 28.1%) were the most frequently involved
sites. Isolated pelvic lymph node involvement was docu-
mented in 1 case, while groin, axillary, and mediastinic
involvement was documented in 2, 1, and 2 cases respec-
tively. Most of the patients (n = 19, 59.4%) showed meta-
static involvement of multiple lymph node stations, and
median size of the lesions was 2.2 cm (range = 1.0–6.0).
In the 28 patients with known Ca125 levels at the time of
recurrence, Ca125 levels were above the normal limit in
26 cases (92.9%). Nineteen (59.4%) patients were treated
with chemotherapy alone, 12 (37.5%) patients were sub-
mitted to radical surgery, followed (n = 11) or not (n = 1)
by chemotherapy, and one patient did not receive any
treatment because of the long PFI (8 years), and the site of
recurrence (mediastinum), which was judged to be at
higher risk for operative complications.
Natural history of ILNR
The median follow up from the initial diagnosis of OC
was 49.5 months (range = 23–149), while the median fol-
low up from the diagnosis of ILNR was 22.5 months
(range = 7–96). A flow-chart of the evolution of patients
since the diagnosis of ILNR is shown in Figure 1. One
patient experienced death of disease, while further pro-
gression was observed in 20 (62.5%) cases after a median
interval of 12 months (range = 4–55) from the diagnosis
of ILNR: 14 of these (70%) again progressed as ILNR,
while 6 cases presented other sites of disease involvement,
including peritoneal carcinomatosis (n = 4), lymph nodes
plus peritoneum plus liver in one case, and lymph nodes
plus brain in the remaining one. Of 14 cases who had pro-
gressed as ILNR, 1 experienced death of disease, and 11
showed further progression: in particular, 6 cases (54.5%)
again progressed as ILNR, while 5 cases presented intra-
abdominal progression. Of 6 cases who kept progressing
at lymph node level, 4 (66.7%) still experienced further
progression as ILNR, while 2 progressed in the abdomen.
At the time of the analysis 9 (28.1%) patients developed
peritoneal disease and 75% of the patients were free from
peritoneal disease at 24 months from the first diagnosis of
ILNR.
Clinical outcomes of patients with ILNR
As of November 2007, all patients were available for sur-
vival analysis. As shown in Figure 2, median survival after
ILNR (PRS) was 37 months, with 69% of the patients sur-
viving more than 2 years after ILNR; median OS from the
diagnosis of OC was 109 months, with all patients surviv-
ing more than 2 years after the initial diagnosis of OC.
Overall, at time of analysis, 11 deaths were observed: 2
deaths were documented in patients progressing as ILNR,
while 9 deaths occurred in the group of patients progress-
ing with intra-abdominal disease at any time during fol-
low up. In particular, in the latter group of patients, the
median survival after the diagnosis of peritoneal disease
was 4 months (range = 2–35).
Analysis of factors predictive of survival after ILNR
Among the clinico-pathological characteristics registered
at initial diagnosis and also at the time of ILNR documen-
tation, a prolonged time to the occurrence of ILNR was
associated with a better prognosis, with a median PRS of
22 months in patients with a PFI within 24 months versus
a median PRS of 60 months in patients with a PFI>24
months (p value = 0.008) (Figure 3). Moreover, a more
favourable outcome was documented in the 12 patients
submitted to cytoreductive surgery for ILNR (1 death,
median PRS = n.r.) compared to the 20 patients who did
not undergo surgery (10 deaths, median PRS = 31
months), although the statistical significance was of bor-
derline value (p value = 0.07). In this context, it is worth
noting that there was no difference in the percentages of
cases with intra-abdominal progression in patients who
received surgical versus medical treatment of the first
ILNR (16.7% versus 21.0%, respectively, p value = 0.6).
Similarly, a trend to a better prognosis was found for
patients younger than 60 years at initial diagnosis (p value
= 0.07). Although the subgroups were too small to gain
statistical significance, we failed to find any association
between the site of ILNR recurrence and prognosis (data
not shown).
Notwithstanding the limited number of patients and
events could restrict the factors which can be included in
the Cox's regression model, in the multivariate analysis
assessing the impact of several factors potentially influ-
encing the outcome of this population (age at diagnosis,
PFI duration, surgical cytoreduction of ILNR), only PFI
retained an independent prognostic role for PRS (p value
= 0.033; χ2 of the model = 7.45, p value of the model =
0.006).
Discussion
Isolated lymph node recurrence (ILNR) of ovarian cancer
(OC) represents a rare but not exceptional pattern of dis-
ease which has recently gained much attention in the lit-
erature [7-10]. In accordance with previously reported
data [7], ILNR occurred in about 6% of our OC patients
representing approximately 10% of the overall recur-
rences. The rate of ILNR in our population, as well as in
other studies not performing systematic lymphadenec-
tomy at initial surgery [7], was similar to the results
reported in series including patients submitted to system-
atic pelvic/para-aortic lymphadenectomy [15-17,24].BMC Cancer 2008, 8:367 http://www.biomedcentral.com/1471-2407/8/367
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Moreover, in two randomised trials comparing systematic
lymphadenectomy versus resection of only bulky lymph
nodes no difference in the percentage of lymph node
recurrences was documented [16,17].
In our series most of the patients exceed 9-years survival
from the initial diagnosis, thus confirming the favourable
prognosis of recurrent OC patients suffering from ILNR
[7-10]: this finding becomes even more relevant consider-
ing that compared to previous studies (Table 3), our
patients were unselected for the duration of PFI, one of
the major determinants of prognosis, and were submitted
to cytoreduction of recurrence in only 37.5% of the cases.
The favourable prognosis of patients with ILNR is unlikely
to be related to the serendipitous selection of patients
with good clinico-pathological features at initial diagno-
sis: indeed, in our series 90.6% of cases were stage IIIc-IV
disease, and 37.5% were not optimally cytoreduced at pri-
mary surgery. Conversely, the median duration of PFI was
longer compared to that usually reported in the overall
OC population [2], thus suggesting that the late occur-
rence of lymph node relapse is intrinsically related to its
more indolent behaviour.
We also showed for the first time that cases presenting
with ILNR keep progressing at lymph node level in a rela-
Flow chart of the events in our patient population (DOD = dead of disease) Figure 1
Flow chart of the events in our patient population (DOD = dead of disease).
ILNR (N=32)
ILNR (N=14)
Other sites of recurrence (N=6)
DOD=4 (peritoneal disease))
Progression (N=11)
Other sites of recurrence (N=5)
DOD=3 (peritoneal disease)
Progression (N=6)
Other sites of recurrence (N=2)
DOD=2 (peritoneal disease)
No Progression (N=11)
DOD (N=1)
Progression (N=20)
No Progression (N=2)
DOD (N=1)
ILNR (N=6)
ILNR (N=4)BMC Cancer 2008, 8:367 http://www.biomedcentral.com/1471-2407/8/367
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tively high percentage of cases: after the first ILNR, pro-
gression of disease was documented in 20 patients and in
70% of them disease was still limited to lymph node sta-
tions; notably, at time of final analysis, 4/20 cases
(25.0%) still continued to show disease only at lymph
node levels suggesting the persistence of long lasting, less
aggressive lymphophilic features. Indeed, after 2 years
from the diagnosis of ILNR 75% of the patients were free
from peritoneal disease.
In the group of patients with ILNR we observed only 2
deaths of disease: one patient presented bulky lympho-
adenopathies infiltrating the cava vein and lumbar verte-
brae, thus hampering the possibility to perform retroperi-
toneal cytoreduction; the other case was a 82 years old
woman who was not operated on because of the presence
of several co-morbidities judged to carry out a very high
risk for operative and postoperative morbidity. On the
other hand, although the development of peritoneal
tumor spreading was shown to be relatively belated, it can
occur any time after the first ILNR progression and it is
rapidly aggressive: at time of analysis all cases progressing
in the peritoneum had experienced death of disease.
In this context, a more in depth understanding of the biol-
ogy of the metastatic process in both primary and recur-
rent OC, through the characterization of the molecular
pathways regulating the pattern of spread to peritoneal or
lymph node stations, would be relevant: indeed, several
factors associated with anti-apoptotic, pro-angiogenic and
pro-invasiveness functions as well as with drug resistance
have been reported to play a role in peritoneal diffusion
[25], while there is scanty data, if any, concerning the biol-
ogy of lymph node route of cancer spreading. We can
hypothesize that the relatively indolent behaviour shown
by ILNR can be related to: i) an intrinsic nature of OC
cells, characterized by low proliferation rates and inability
to initially express molecules associated with peritoneal
spreading; ii) the peculiar microenvironment of the
lymph node, where T cells and cytokines may keep tumor
cells in a dormant state thus containing tumor spread. The
analysis of the immunological characteristics of the
lymph node's cell population, together with the patholog-
ical features of the tumor infiltration (e.g. microscopic
with T cell infiltration versus massive neoplastic invasion)
and, the molecular characterization of the tumor cells
through genomic/proteomic techniques, could be partic-
ularly useful to understand the different clinical behav-
iour associated with distinct patterns of tumor
dissemination.
Finally, we showed that among the features potentially
affecting the clinical outcome after ILNR, a long duration
of PFI as well as the surgical removal of ILNR, were asso-
ciated with a more favourable prognosis; this data is not
surprising considering that platinum sensitivity represents
the major determinant of prognosis in recurrent OC
patients, together with surgical cytoreduction of the recur-
rent lesion in selected clinical setting [5,6]. It could be
argued that in our series the diagnosis of ILNR was surgi-
cally confirmed only in 37.5% of the cases, thus leading to
a potential underestimation of the presence of peritoneal
lesions, as suggested by Bristow et al. [26], who docu-
mented the presence of occult intraperitoneal disease in
21.4% of ILNR even when PET/CT scan techniques were
used. However, our data shows similar percentages of
intra-abdominal progression in patients who had surgical
versus medical treatment of the first ILNR, thus suggesting
Overall Survival (OS), and Post-Relapse Survival (PRS) of the  whole study population Figure 2
Overall Survival (OS), and Post-Relapse Survival 
(PRS) of the whole study population.
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that the favourable role of cytoreductive surgery is more
reasonably related to removal of the disease rather than to
the selection of cases without peritoneal seeding.
Although in multivariate analysis only the long duration
of PFI was shown to maintain its favourable prognostic
role for PRS, the usefulness of surgical exploration of
patients with suspected ILNR should be not underesti-
Table 3: Clinical/pathological features at initial diagnosis and outcome details of OC patients recurring as ILNR: data from the 
available literature
Author Blanchard et al. [7] Benedetti Panici et al. 
[8]
Santillan et al. [9] Uzan et al. [10] Current study
ILNR
- N° of cases 27 19 25 12 32
- % of OC recurrences n.r. n.r. n.r. n.r. 10.6
- % of OC 4.2 n.r. n.r. n.r. 6.1
Stage III-IV 67% 60% 72% 50% 94%
RT at first surgery >2 cm n.r. <5%a 8% 8.3% 37.5%
Poor differentiated n.r. 60% 100% n.r. 68%
Systematic 
lymphadenectomy at first 
surgery
00 0 0 0
Complete response after 
Initial treatment
59.3% n.r. 100% n.r. 65.6%
Histological diagnosis of 
ILNR
63% 100% 100% 100% 37.5%
Cases with CA125 levels
>35 U/ml at the time of 
ILNR
92% 60% 50% 100% 93%
PFI, months Median 
(range)
26 (1–159) 14 (7–84) 16 (6–40) 21 (6–72) 17.5 (1–130)
Site of ILNR
-Aortic N° (%) 15 (55.5%) 30 (75%)b 16 (64%) 7 (58.3%) 23 (71.9%) b
-Pelvic N° (%) 4 (14.8%) 10 (25%) 4 (16%) 5 (41.7%) 1 (3.1%)
-Other N° (%) 14 (51.8%) n.r. 6 (24%) 2 (16.7%) 8 (25.0%)
Secondary cytoreduction 29.6% 72.5% 100% 100% 37.5%
Median follow up duration 
from ILNR diagnosis (mts)
n.r. 26 19 50 19.5
Median PRS (mts) 26 >60 37 >60 37
Median OS (mts) 68 n.r. 61 114 109
Prognostic factors 
influencing PRS
None -Secondary cytoreduction None n.r. -PFI>24 mts
-Secondary surgery
n.r. = not reported
a Residual tumor > 1 cm
b Para-aortic with or without pelvic lymph node involvementBMC Cancer 2008, 8:367 http://www.biomedcentral.com/1471-2407/8/367
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mated, and complete surgical resection of lymph node
stations should be attempted in the absence of diffuse
peritoneal disease, given the overall localized and slowly
growing features of lymph node disease.
Conclusion
In conclusion, although these findings need to be con-
firmed in a larger series, ILNR seems to represent a less
aggressive pattern of disease relapse which keeps progress-
ing as ILNR in a discrete proportion of cases. On the other
hand, the relatively belated occurrence of peritoneal
spreading may occur any time after the first ILNR docu-
mentation and is necessarily associated with a rapidly
fatal outcome.
The multiparametric molecular characterization of perito-
neal and lymph node disease, in both primary and recur-
rent OC, would possibly provide useful information in
the future.
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